Cipla to acquire 32.49 percent stake in solar power firm AMP Energy Green Eleven

Published On 2022-02-06 04:45 GMT   |   Update On 2022-02-06 04:46 GMT

New Delhi: Drug major Cipla has recently announced that the company has signed a pact to acquire 32.49 per cent stake in AMP Energy Green Eleven to set up a captive solar power project in Maharashtra. The company has entered into a shareholder's agreement along with the power purchase agreement to acquire up to 32.49 per cent stake on a fully diluted basis in AMP Energy Green Eleven,...

Login or Register to read the full article

New Delhi: Drug major Cipla has recently announced that the company has signed a pact to acquire 32.49 per cent stake in AMP Energy Green Eleven to set up a captive solar power project in Maharashtra.

The company has entered into a shareholder's agreement along with the power purchase agreement to acquire up to 32.49 per cent stake on a fully diluted basis in AMP Energy Green Eleven, the Mumbai-based company said in a regulatory filing. 

Post-acquisition, AMP Energy Green Eleven Private Limited, will become an associate of Cipla Limited. Subscription to equity shares and compulsorily convertible debentures shall be completed within 2 months from the date of the signing of the transaction documents, or such other date to be mutually agreed between the parties. 

Cost of acquisition of 32.49% stake is up to Rs. 7,50,00,000/- (Rupees Seven Crore Fifty Lakhsonly) on a fully diluted basis.

The acquisition is in line with the commitment to enhance the share of renewable power sources in its operation and to comply with regulatory requirements for being a captive user under Indian electricity laws, Cipla was quoted as saying by PTI.

AMP Energy Green Eleven was incorporated on November 21, 2020, and is engaged in the business of generating and supplying electrical power generated using solar energy.
In a separate filing, Cipla said its Global Chief Financial Officer Kedar Upadhye has resigned from the company.   
Upadhye will serve his full notice period of three months upto close of business hours of May 3, 2022, it added.  
The company's board will announce his successor in due course, the drug firm said.

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.

Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.

Tags:    
Article Source : with agency inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News